NASH Drug Developers Are Seeking Faster, More Specific
& Cost-Effective Solutions

150+ dedicated NASH drug developers from leading biopharma including Gilead, Novo Nordisk, Takeda, Eli Lilly, Pfizer, AstraZeneca, Ionis, Gilead, Hemoshear Therapeutics, Merck, Novartis and more will virtually unite this year at the 5th NASH Summit.

Our highly engaged audience of NASH experts are actively seeking to collaborate with organizations that can help them solve solutions in the development of clinically effective therapies for NASH. If you’re looking to showcase your solutions, generate new business leads, and source opportunities for partnerships with senior decision makers in the NASH field, we have a strictly limited number of partnership opportunities available including virtual speaking positions across our dedicated discovery, translational and clinical tracks, plus plenary sessions.

  • Secure a virtual exhibition booth to present and position your capabilities to developers who are actively seeking new solutions to optimize drug development inefficiencies
  • Network one-to-one with stakeholders during our coordinated networking sessions to first-hand understand their requirements and present your solution
  • Deliver a presentation online and still be able to influence the thinking of the most engaged NASH industry experts working to identify new promising compounds


We’ll work with you to build a bespoke partnership package focused on making valuable connections and generating actionable leads to ensure you meet your 2021/2022 commercial objectives in this new digital reality. Contact us by clicking the button below.

nash stats
nash stats 2

Discover what our 2019 partners thought of the event: